TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Cg Oncology
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates

CG Oncology initiated a rolling Biologics License Application for cretostimogene, a potential bladder cancer treatment, demonstrating promising 24-month complete response rates and completing enrollment in a Phase 3 clinical trial for non-muscle invasive bladder cancer.

Insights
CGON   positive

Company showed significant progress in drug development, completed key clinical trial milestones, initiated FDA submission, and maintained strong cash position to fund operations through 2028